Introduction
============

Total hip arthroplasty (THA) and total knee arthroplasty (TKA) are operations with a high risk of venous thromboembolic (VTE) complications and in the latest ACCP guidelines it is recommended to use prophylaxis with a low-molecular-weight heparin (LMWH), fondaparinux (a synthetic pentasaccharide) or adjusted-dose vitamin K antagonist (VKA) for at least 10 days after operation and to give extended prophylaxis for 28--35 days after THA and hip fracture surgery ([@b10-vhrm-4-0855]). Administration of LMWH and fondaparinux is subcutaneous and therefore these drugs are less suited for self-administration after discharge. Extended prophylaxis with enoxaparin after THA was cost-effective only when more than half of all patients were able to self-inject their treatment ([@b1-vhrm-4-0855]). Although administered orally, VKA is inconvenient to use due to the narrow therapeutic window and the need for repeated dose adjustments requiring laboratory monitoring. Thus, it has long been hoped that more convenient oral antithrombotic drugs would be discovered. The first step in this direction was when ximelagatran, an oral direct thrombin inhibitor, was introduced on the market. However, when safety reports from patients on extended prophylaxis after major orthopedic surgery indicated a risk of liver toxicity it was eventually withdrawn ([@b15-vhrm-4-0855]). Since then several other oral anticoagulant compounds have been developed and they are currently undergoing clinical evaluation in orthopedic surgery ([@b3-vhrm-4-0855], [@b6-vhrm-4-0855]; [@b24-vhrm-4-0855]). One of these is rivaroxaban (Xarelto^®^; Bayer HealthCare), a direct factor Xa (FXa) inhibitor ([@b30-vhrm-4-0855]).

Review of pharmacology, mode of action, pharmacokinetics of factor Xa inhibitors
================================================================================

Activation of factor X to FXa initiates the conversion of prothrombin to thrombin which leads to conversion of fibrinogen to fibrin and eventually clot formation ([Figure 1](#f1-vhrm-4-0855){ref-type="fig"}). An invasive operative procedure cannot be performed without tissue damage resulting in release of tissue factor (TF). Orthopedic surgery due to surgical damage to bone is especially prone to TF release because bone marrow is rich in TF ([@b2-vhrm-4-0855]). In conjunction with factor VIIa, TF activates FXa directly (the extrinsic pathway) or via propagation of the tenase complex (factor VIIIa + factor IXa) on an activated platelet membrane (the intrinsic pathway) (Mann et al 2003). The prothrombinase complex is then formed on the platelet surface and incorporation of FXa into this complex increases the rate of thrombin generation tremendously. The thrombingenerating efficacy of the prothrombinase complex is much more pronounced than that of free FXa ([@b26-vhrm-4-0855]; [@b31-vhrm-4-0855]; [@b27-vhrm-4-0855]). Thus, FXa is the pivotal point in the coagulation cascade because it can be activated both by the extrinsic and the intrinsic pathways; furthermore the only function of FXa in the coagulation process is to promote coagulation and to amplify the events. Thus, it has been estimated that one molecule of FXa catalyzes the formation of \~1000 thrombin molecules ([@b28-vhrm-4-0855]). In the design of new antithrombotic drugs it therefore seems attractive to target the mode of action towards inhibition of FXa. Unfractionated heparin (UFH) and LMWH are indirect FXa inhibitors because they inhibit FXa by potentiation of the natural inhibitory action of antithrombin (AT) that is an endogeneous plasma protein. In addition especially UFH also has an inhibitory action on several other coagulation factors among which factor IIa is the most important. Fondaparinux is a synthetic pentasaccharide with the same mode of action as UFH and LMWH, but in contrast to those it acts solely by the antithrombin-mediated inhibition of FXa ([@b32-vhrm-4-0855]). On the contrary, direct FXa inhibitors, including rivaroxaban, do not need AT to exert their inhibitory action on FXa, because they are able to bind directly to the active site of FXa, thereby preventing interaction with its substrates. As a consequence the direct FXa inhibitors are able to inhibit both free FXa and FXa bound in the prothrombinase complex ([@b30-vhrm-4-0855]) ([Figure 1](#f1-vhrm-4-0855){ref-type="fig"}).

Rivaroxaban belongs to a new group of oral direct FXa inhibitors. The chemical structure is shown in [Figure 2](#f2-vhrm-4-0855){ref-type="fig"} and pharmacologic features are listed in [Table 1](#t1-vhrm-4-0855){ref-type="table"}. The absorption after oral intake is near 100%. C~max~ is reached within 2--4 hours ([@b16-vhrm-4-0855]) and is slightly enhanced by food intake, irrespective of type of food ([@b18-vhrm-4-0855]). The bioavailability is near 80% ([@b17-vhrm-4-0855]). The elimination is unchanged via the renal and the fecal/biliary routes ([@b20-vhrm-4-0855]).

Preclinical studies
===================

In vitro studies have shown that rivaroxaban can inhibit both free FXa and FXa bound in the prothrombinase complex more potently in human and rabbit plasma than in rat plasma. The antithrombotic effect of rivaroxaban has also been studied in vivo in rat and rabbit models. In a rat venous stasis model rivaroxaban reduced venous thrombosis in a dose-dependent fashion and was able to reduce arterial thrombus formation in an arteriovenous shunt in both rats and rabbits. When given in antithrombotic doses (3 mg per kg po) rivaroxaban did not affect bleeding time significantly in rats or rabbits ([@b30-vhrm-4-0855]).

The pharmacokinetic and pharmacodynamic features of rivaroxaban were studied in a number of studies in healthy human subjects. In a single-dose escalation study, with placebo control, doses of rivaroxaban of 5--80 mg orally were studied in 108 male subjects. The study showed a dose-dependent inhibition of FXa and an additional prolongation of prothrombin time (PT), which correlated with the plasma concentration of rivaroxaban. The new drug was well tolerated and there was no increased risk of bleeding compared with placebo ([@b17-vhrm-4-0855]). In a placebo-controlled multiple dose escalation study, rivaroxaban doses of 5 mg once, twice, and thrice daily, and 10 mg, 20 mg, and 30 mg twice daily were administered orally on days 0 and 3--7. The study showed no clinically relevant influence on bleeding time after treatment for 7 days and there were no signs of accumulation at any dose. A dose-dependent prolongation of PT, activated partial thromboplastin time (aPTT), and HepTest to a similar extent to inhibition of FXa were seen, and it was suggested that the inhibition of the FXa activity of rivaroxaban can be monitored by these clotting tests or by measurement of FXa alone ([@b16-vhrm-4-0855]). None of the studies showed problems with tolerability or safety with any dose or dosing frequency of rivaroxaban.

A number of interaction studies in healthy subjects between rivaroxaban and commonly used drugs such as acetyl salicylic acid (ASA) and nonsteroid acetylsalicylic acids (NSAID) were performed. Concomitant use of ASA in 500 mg and 100 mg doses and rivaroxaban at doses between 5 mg and 80 mg did not show any clinically relevant interaction ([@b20-vhrm-4-0855]). Rivaroxaban together with NSAID (naproxen) significantly increased bleeding time compared with rivaroxaban alone, but it was not clinically relevant ([@b21-vhrm-4-0855]). A comparative placebo-controlled study in 50 subjects treated with rivaroxaban or moxifloxacin (positive control) showed no prolongation of the QT-interval of rivaroxaban, and thus there is no need to monitor the QT-interval routinely in patients treated with rivaroxaban ([@b23-vhrm-4-0855]).

With a half-life of 5--9 hours it would be expected that rivaroxaban should be administered at least twice daily to be effective. However, a crossover placebo-controlled study in which 12 healthy subjects received single oral doses of 5--30 mg of rivaroxaban showed that the endogenous thrombin potential was dose-dependently reduced by more than 80%, compared with baseline, and that the prothrombinaseinduced clotting time in platelet-rich plasma was prolonged more than 1.8 times, both effects having a duration of 24 hours ([@b13-vhrm-4-0855]). Thus, this would support a concept of once-daily administration. The clinical impact of these findings was further explored in the phase II program.

Phase II program (dose finding)
===============================

A series of dose-ranging studies was performed in patients undergoing THA or TKA and an overview of the results of these studies is given in [Table 2](#t2-vhrm-4-0855){ref-type="table"}. The first proof-of-principle study, which included patients undergoing THA, was an open-label, randomized study to assess the efficacy and safety of different doses of rivaroxaban relative to a standard regimen of enoxaparin ([@b7-vhrm-4-0855]). Rivaroxaban was given as tablets in doses of 2.5 mg, 5 mg, 10 mg, 20 mg, and 30 mg twice daily and 30 mg once daily, started 6--8 h after surgery; enoxaparin was given by subcutaneous injection of 40 mg once daily started on the evening before surgery. The investigators were blinded to the dose of rivaroxaban, but not to the type of prophylaxis (rivaroxaban vs enoxaparin). The treatment continued for 5--9 days at which time a bilateral venography was performed to diagnose asymptomatic deep vein thrombosis (DVT); in cases of symptoms of DVT or pulmonary embolism (PE) during the study objective confirmation of the event was requested. The efficacy results with rivaroxaban were comparable with that obtained with enoxaparin, but with a flat dose response. The incidences of major bleeding were dose-dependent and at an acceptable level. In patients treated with rivaroxaban 30 mg once daily the efficacy result was comparable with the result in the enoxaparin group (15.1% vs16.8%) and the incidence of major bleeding (4.5%) was within the expected range, which was the first indication that once-daily administration of rivaroxaban could be feasible ([Table 2](#t2-vhrm-4-0855){ref-type="table"}). The next two studies to follow were randomized, double-blind studies in THA or TKA patients, respectively ([@b33-vhrm-4-0855]; [@b4-vhrm-4-0855]). The dose regimens of rivaroxaban were 2.5 mg, 5 mg, 10 mg, 20 mg, and 30 mg administered orally twice daily started 6--8 h after surgery and the comparator was again subcutaneous injections of enoxaparin, 40 mg once daily started on the evening before surgery in the THA study, and 30 mg twice daily started 12--24 h after surgery in the TKA study. The duration of the treatment and timing of venography was the same as for the previously described study. The efficacy results obtained in both studies again showed a flat dose-response for rivaroxaban with incidences in the different dose groups that were comparable with the enoxaparin group in the individual study. The incidences of VTE in both treatment arms of the TKA study were much higher (25.4%--40.4% in the rivaroxaban groups and 44.3% in the enoxaparin group) than those seen in the THA study (7%--18% in the rivaroxaban groups and 17% in the enoxaparin group) ([Table 2](#t2-vhrm-4-0855){ref-type="table"}), which is not surprising after knee surgery based on previous reports ([@b12-vhrm-4-0855]; [@b10-vhrm-4-0855]). The safety results with rivaroxaban were also at a comparable level with enoxaparin and clearly dose-dependent ([Table 2](#t2-vhrm-4-0855){ref-type="table"}). A pooled analysis of the two studies showed that total daily doses of rivaroxaban of 5--20 mg had the most favorable balance between antithrombotic efficacy and safety compared with enoxaparin ([@b11-vhrm-4-0855]). The last study in the phase II program was performed in patients undergoing THA, and in contrast to the previous studies it was decided that rivaroxaban was to be administered once daily in all dose groups ([@b5-vhrm-4-0855]). The following once-daily doses of rivaroxaban were studied: 5 mg, 10 mg, 20 mg, 30 mg, and 40 mg started 6--8 h after surgery, and for the comparator arm enoxaparin 40 mg injected subcutaneously once daily started on the evening before surgery was chosen. Treatment duration and timing of venography was the same as for the previously described studies. The primary efficacy end-point was observed in 6.4%--14.9% of patients in the different rivaroxaban dose groups, without any dose relation, and in 25.2% of the enoxaparin group; however, the study was not powered to show any statistical significance ([Table 2](#t2-vhrm-4-0855){ref-type="table"}). The primary safety end-point was observed in 0.7%--5.1% of patients in the rivaroxaban groups, with a significant dose-dependency, compared with 1.9% in the enoxaparin group. When compared with the safety results of the previous study in THA using twice-daily dosing of rivaroxaban the results did not differ much for total daily doses of 5 mg (0.8% vs 2.3%), 10 mg (0.7% vs 2.2%), 20 mg (4.3% vs 2.3%), and 40 mg (5.1% vs 4.5%) ([@b4-vhrm-4-0855]). Thus, once-daily dosing of rivaroxaban did not seem to increase the risk of bleeding compared with twice-daily dosing.

In the entire phase II program all adverse reactions observed in the treatment groups were registered. To follow the liver function repeated measurements of liver aminotransferase levels such as alanine aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin levels up to 7 days after the last dose of study medication were performed. In the second THA study in phase II ([@b4-vhrm-4-0855]) ALT or AST levels \>3 times the upper limit of normal (ULN) occurred in 11.2% and 8.8% of patients in the enoxaparin group compared with 3.9%--6.4% and 3.3%--8.3%, respectively, in the rivaroxaban groups. In the phase II TKA study ([@b33-vhrm-4-0855]), elevated levels of ALT and AST (\>3x ULN) and of bilirubin (2x ULN) were seen in 4 patients in the rivaroxaban groups. Two of these patients with elevated ALT and bilirubin remained on treatment without clinical symptoms. All changes returned to normal at follow-up. In the THA study with once-daily administration of rivaroxaban ([@b5-vhrm-4-0855]), ALT or AST levels \>3x ULN occurred in 7.1% and 7.1% of patients in the enoxaparin group compared with 3.0%--5.4% and 3.4%--6.2%, respectively, in the rivaroxaban groups. One patient treated with rivaroxaban 30 mg od for 7 days showed elevation of ALT \>3x ULN and bilirubin \>2x ULN 3 h after the first drug administration. Both returned to normal at follow-up despite continued treatment. In a patient treated with rivaroxaban 10 mg od for 7 days, who eventually had a diagnosis of cholecystolithiasis, liver enzymes continued to rise after treatment cessation. In general, none of the studies showed any dose-dependency between rivaroxaban and increased liver parameters. Based on the findings in the phase II program, however, it was not possible to determine whether there was a relationship between rivaroxaban and liver function impairment. Another open question after the phase II program was whether there was an increased risk of liver function impairment when rivaroxaban was given for thromboprophylaxis on an extended basis (up to 35 days), which was seen with ximelagatran ([@b15-vhrm-4-0855]).

Rationale for dose selection
============================

In general, when a dose of any new anticoagulant has to be selected both efficacy and safety should be taken into consideration and a perfect balance is preferable. A population analysis was performed to compare the pharmacodynamics and pharmacokinetics of total daily doses of rivaroxaban of 5 mg, 10 mg, and 20 mg ([@b29-vhrm-4-0855]) using blood samples collected in the previously mentioned clinical phase II studies with once- or twice-daily dosing of rivaroxaban in patients undergoing THA ([@b4-vhrm-4-0855], [@b5-vhrm-4-0855]). It was found that both maximum and minimum plasma concentrations of rivaroxaban were lower after once-daily compared with twice-daily administration, but with overlapping 90% confidence intervals. The pharmocokinetic properties of rivaroxaban were found to be independent of the dosing regimen ([@b29-vhrm-4-0855]). In a blinded, placebo-controlled study in healthy volunteers, the effect of body weight (BW) and gender on the efficacy and safety of a single 10 mg dose of rivaroxaban were assessed. The study showed no influence of extreme BW (\> 120 kg) compared with normal BW (70--80 kg) on the C~max~ of rivaroxaban, but it was increased by 24% in female subjects weighing 50 kg or less, resulting in a 15% prolongation of PT; however, this result had no clinical relevance. In addition, because gender or BW did not affect the area under the curve, dose adjustment would not be necessary ([@b22-vhrm-4-0855]). Based on the rates of the primary safety end-point in the last phase II study, it was obvious that total daily rivaroxaban doses of 5--10 mg were comparable to those seen in the enoxaparin group, 0.7% and 0.8%, respectively, vs 1.9%. On the contrary, the rates of the primary efficacy end-point in these two rivaroxaban groups were clearly lower compared with enoxaparin, 14.9 and 10.6, respectively vs 25.2% ([Table 2](#t2-vhrm-4-0855){ref-type="table"}) ([@b5-vhrm-4-0855]). Summarizing these results, it was decided that a once-daily dosage of 10 mg of rivaroxaban should be studied in the phase III program in orthopedic surgery.

Phase III program
=================

The clinical phase III program in orthopedic surgery was given the acronym: RECORD ([R]{.ul}egulation of [C]{.ul}oagulation in major [O]{.ul}rthopaedic surgery reducing the [R]{.ul}isk of [D]{.ul}VT and PE). The RECORD program consists of the four clinical prophylaxis studies presented in [Table 3](#t3-vhrm-4-0855){ref-type="table"}. All studies were prospective, double blind, randomized studies comparing the antithrombotic efficacy and safety of rivaroxaban 10 mg given orally once daily and enoxaparin 40 mg once daily or 30 mg twice daily in patients undergoing THA or TKA. RECORD 1 and RECORD 2 were performed in THA patients and 40 mg once daily of enoxaparin was used for comparison in both studies. In RECORD 1 both prophylactic regimens were given for a total duration of 35 ± 4 days (long term), whereas in RECORD 2 only rivaroxaban was given long term compared with enoxaparin which was given for 10--14 days (short term) ([Table 3](#t3-vhrm-4-0855){ref-type="table"}), because it is not universally accepted to use long-term prophylaxis after THA in spite of the recommendation in the ACCP guidelines ([@b10-vhrm-4-0855]). RECORD 3 and RECORD 4 were performed in TKA patients with short-term duration (10--14 days) of both regimens, because long-term prophylaxis is not recommended after TKA ([@b10-vhrm-4-0855]). In RECORD 3, 10 mg of rivaroxaban once daily started 6--8 h after surgery was compared with 40 mg of enoxaparin started in the evening before surgery, whereas in RECORD 4 enoxaparin 30 mg twice daily started 12--24 h after surgery was used in the comparator arm ([Table 3](#t3-vhrm-4-0855){ref-type="table"}). The efficacy results of the RECORD studies are presented in [Tables 4](#t4-vhrm-4-0855){ref-type="table"} and [5](#t5-vhrm-4-0855){ref-type="table"}. In all studies rivaroxaban was significantly more effective in reducing the primary efficacy end-point, the composite of the incidence of any DVT (proximal and/or distal), nonfatal symptomatic, objectively confirmed PE and all cause deaths and major VTE, the composite of proximal DVT, PE, and VTE-related death, compared with enoxaparin ([Table 4](#t4-vhrm-4-0855){ref-type="table"}). In the RECORD 2 and RECORD 3 studies, rivaroxaban also significantly reduced the incidence of symptomatic VTE events compared with enoxaparin ([Table 5](#t5-vhrm-4-0855){ref-type="table"}), which are important clinical observations. The safety (the incidence of major and/or minor bleeding events) of rivaroxaban was comparable with enoxaparin in all the phase III studies ([Table 6](#t6-vhrm-4-0855){ref-type="table"}). The RECORD 4 study has been finalized very recently, but no results have been released yet. The liver safety parameters showed no important differences between rivaroxaban and enoxaparin, and no different action was observed on liver function when rivaroxaban was used for long-term prophylaxis in the RECORD 1 and RECORD 2 studies compared with short-term prophylaxis with rivaroxaban. A more detailed description of these results cannot be given because the studies have been published only in abstract form.

Patient-focused perspectives such as quality of life, patient satisfaction/acceptability
========================================================================================

The ideal antithrombotic is a drug with a broad therapeutic window in terms of efficacy versus safety (bleeding), with a rapid onset and offset of action, with a high bioavailability and minimal food and drug interactions after oral administration, and predictable pharmacodynamics and pharmacokinetics with no requirement for dose adjustment and coagulation monitoring. For the patient, such a drug would be easy to handle in everyday life, and therefore patient acceptability would be easily obtained. When we consider the clinical behavior of rivaroxaban in phase II and III it seems that it comes close to this ideal. However, there are still some outstanding questions to be resolved, such as the influence of impaired renal function on drug safety, the lack of an antidote in case of a bleeding event, and patients with nausea and vomiting after surgery being unable to take the medication as planned, and patients with indwelling epidural catheters. Based on previous experience, the cost-effectiveness of a new drug compared with existing alternatives is also important for clinicians deciding whether to use a new drug. Competition from other new drugs on the market is also important. Dabigatran etexilate, an oral direct thrombin inhibitor, has recently been approved in Europe for thromboprophylaxis in orthopedic settings. In a recent prospective study, dabigatran etexilate was as effective and safe as enoxaparin 40 mg od in reducing the risk of VTE after THA ([@b9-vhrm-4-0855]). Within the near future it will be settled if both drugs will be approved and then only a direct comparison in a relevant clinical study can show which of the drugs that has the most profitable efficacy and safety.

Conclusions, therapeutic potential
==================================

Rivaroxaban -- an oral, direct FXa inhibitor -- is a new compound for VTE prophylaxis after orthopedic surgery. The drug has predictable pharmacokinetics and pharmacodynamics and needs no coagulation monitoring or dose adjustment. Results from phase II and phase III clinical studies have shown that rivaroxaban, at a once-daily dosage of 10 mg, has a significantly better efficacy and a comparable safety compared with enoxaparin in patients undergoing THA and TKA.
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###### 

Pharmacologic features of rivaroxaban taken orally

  Absorption        \~100%
  ----------------- ---------------------
  C~max~            2--4 hours
  t~½~              5--9 hours
  Bioavailability   \~80%
  Elimination       renal fecal/biliary

###### 

Overview of the results of the four clinical studies in phase II (per-protocol data)

                             Design                     Doses (mg)                                                          N                                                   Efficacy[a](#tfn1-vhrm-4-0855){ref-type="table-fn"}(%)   Safety[b](#tfn2-vhrm-4-0855){ref-type="table-fn"}(%)                                   
  -------------------------- -------------------------- ------------------------------------------------------------------- --------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------ ------------ ------ ----------- -----
  THA ([@b7-vhrm-4-0855])    Open, randomized           2.5, 5, 10, 20, 30 bid[c](#tfn3-vhrm-4-0855){ref-type="table-fn"}   40 od[d](#tfn4-vhrm-4-0855){ref-type="table-fn"}    359                                                      107                                                    10.2--23.8   16.8   2.5--10.8   0
                                                        30 od[c](#tfn3-vhrm-4-0855){ref-type="table-fn"}                                                                                                                                                                                        15.1                4.5         
  THA ([@b4-vhrm-4-0855])    Double-blind, randomized   2.5, 5, 10, 20, 30 bid[c](#tfn3-vhrm-4-0855){ref-type="table-fn"}   40 od[d](#tfn4-vhrm-4-0855){ref-type="table-fn"}    442                                                      106                                                    7--18        17     0.8--5.4    1.5
  TKA ([@b33-vhrm-4-0855])   Double-blind, randomized   2.5, 5, 10, 20, 30 bid[c](#tfn3-vhrm-4-0855){ref-type="table-fn"}   30 bid[e](#tfn5-vhrm-4-0855){ref-type="table-fn"}   296                                                      70                                                     25.4--40.4   44.3   1--7.5      1.9
  THA ([@b5-vhrm-4-0855])    Double-blind, randomized   5, 10, 20, 30, 40 od                                                40 od[d](#tfn4-vhrm-4-0855){ref-type="table-fn"}    511                                                      107                                                    6.4--14.9    25.2   0.7--5.1    1.9

^a^Primary efficacy end-point was the composite of the incidence of any deep vein thrombosis (proximal and/or distal), nonfatal symptomatic, objectively confirmed pulmonary embolism and all cause deaths.

^b^Primary safety end-point was the incidence of major bleeding (according to preset criteria) starting after the first postoperative dose of study drug, but no later than 2 days after the last dose of study drug.

^c^Started 6--8 h after surgery (tablets).

^d^Started on the evening before surgery (injected subcutaneously).

^e^Started 12--24 h after surgery (injected subcutaneously).

**Abbreviations:** THA, total hip arthroplasty; TKA, total knee arthroplasty; riva, rivaroxaban; enox, enoxaparin.

###### 

Design of the double blind, randomized phase III prophylaxis studies in orthopedic surgery

  Study title (reference)         Operation   Doses (mg)                                         Duration of prophylaxis (days)                               
  ------------------------------- ----------- -------------------------------------------------- --------------------------------------------------- -------- --------
  RECORD 1 ([@b8-vhrm-4-0855])                10 od[a](#tfn7-vhrm-4-0855){ref-type="table-fn"}   40 od[b](#tfn8-vhrm-4-0855){ref-type="table-fn"}    35 ± 4   35 ± 4
  RECORD 2 ([@b14-vhrm-4-0855])   THA         10 od[a](#tfn7-vhrm-4-0855){ref-type="table-fn"}   40 od[b](#tfn8-vhrm-4-0855){ref-type="table-fn"}    35 ± 4   10--14
  RECORD 3 ([@b25-vhrm-4-0855])   TKA         10 od[a](#tfn7-vhrm-4-0855){ref-type="table-fn"}   40 od[b](#tfn8-vhrm-4-0855){ref-type="table-fn"}    10--14   10--14
  RECORD 4                        TKA         10 od[a](#tfn7-vhrm-4-0855){ref-type="table-fn"}   30 bid[c](#tfn9-vhrm-4-0855){ref-type="table-fn"}   10--14   10--14

^a^Started 6--8 h after surgery (tablets).

^b^Started on the evening before surgery (injected subcutaneously).

^c^Started 12--24 h after surgery (injected subcutaneously).

**Abbreviations:** THA, total hip arthroplasty; TKA, total knee arthroplasty; riva, rivaroxaban; enox, enoxaparin.

###### 

Efficacy results in the phase III studies of the RECORD program

  Study title (reference)         N (randomized)   Primary efficacy end-point[a](#tfn11-vhrm-4-0855){ref-type="table-fn"}(major VTE[b](#tfn12-vhrm-4-0855){ref-type="table-fn"}) %   Relative risk reduction %   P-value for difference   
  ------------------------------- ---------------- --------------------------------------------------------------------------------------------------------------------------------- --------------------------- ------------------------ -------------------
  RECORD 1 ([@b8-vhrm-4-0855])    3135 (4541)      1.1 (0.2)                                                                                                                         3.7 (2.0)                   70 (88)                  \<0.001 (\<0.001)
  RECORD 2 ([@b14-vhrm-4-0855])   1723 (2509)      2.0 (0.6)                                                                                                                         9.3 (5.1)                   79 (88)                  \<0.001 (\<0.001)
  RECORD 3 ([@b25-vhrm-4-0855])   1702 (2531)      9.6 (1.0)                                                                                                                         18.9 (2.6)                  49 (62)                  \<0.001 (0.016)

^a^Primary efficacy end-point was the composite of the incidence of any deep vein thrombosis (DVT) (proximal and/or distal), nonfatal symptomatic, objectively confirmed pulmonary embolism (PE) and all cause deaths.

^b^Major venous thromboembolism (VTE): the composite of proximal DVT-, PE-, and VTE-related death.

**Abbreviations:** riva, rivaroxaban; enox, enoxaparin.

###### 

Symptomatic venous thromboembolic (VTE) events in the phase III studies of the RECORD program

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study title (reference)         Symptomatic VTE[a](#tfn14-vhrm-4-0855){ref-type="table-fn"} n/N (%)   Relative risk reduction %   P-value for difference   
  ------------------------------- --------------------------------------------------------------------- --------------------------- ------------------------ -------
  RECORD 1 ([@b8-vhrm-4-0855])    6/2195\                                                               11/2206\                    --                       0.22
                                  (0.3)                                                                 (0.5)                                                

  RECORD 2 ([@b14-vhrm-4-0855])   3/1212\                                                               15/1207\                    80                       0.004
                                  (0.2)                                                                 (1.2)                                                

  RECORD 3 ([@b25-vhrm-4-0855])   8/1201\                                                               24/1217\                    66                       0.005
                                  (0.7)                                                                 (2.0)                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Symptomatic VTE = objectively verified deep vein thrombosis and/or pulmonary embolism occurring during the study.

**Abbreviations:** riva, rivaroxaban; enox, enoxaparin.

###### 

Safety results of the phase III studies in the RECORD program

  Study title (reference)         Safety population   Major bleeding[a](#tfn16-vhrm-4-0855){ref-type="table-fn"}%   Non-major bleeding[b](#tfn17-vhrm-4-0855){ref-type="table-fn"}%         
  ------------------------------- ------------------- ------------------------------------------------------------- ----------------------------------------------------------------- ----- -----
  RECORD 1 ([@b8-vhrm-4-0855])    4433                0.3                                                           0.1                                                               5.8   5.8
  RECORD 2 ([@b14-vhrm-4-0855])   2457                0.1                                                           0.1                                                               5.5   6.5
  RECORD 3 ([@b25-vhrm-4-0855])   2459                0.6                                                           0.5                                                               4.3   4.4

^a^Primary safety end-point was the incidence of major bleeding (according to preset criteria) starting after the first postoperative dose of study drug, but no later than 2 days after the last dose of study drug.

^b^All bleeding events that were not fulfilling the criteria of being major.

**Abbreviations:** riva, rivaroxaban; enox, enoxaparin.
